TY - JOUR
T1 - A possible association between missense polymorphism of the breakpoint cluster region gene and lithium prophylaxis in bipolar disorder
AU - Masui, Takuya
AU - Hashimoto, Ryota
AU - Kusumi, Ichiro
AU - Suzuki, Katsuji
AU - Tanaka, Teruaki
AU - Nakagawa, Shin
AU - Suzuki, Tatsuyo
AU - Iwata, Nakao
AU - Ozaki, Norio
AU - Kato, Tadafumi
AU - Takeda, Masatoshi
AU - Kunugi, Hiroshi
AU - Koyama, Tsukasa
N1 - Funding Information:
The authors thank Ms. Tomoko Shizuno and Keiko Okada for their technical assistance. This work was supported in part by Grants-in-Aid from the Japanese Ministry of Health, Labor and Welfare, the Japanese Ministry of Education, Culture, Sports, Science and Technology, CREST (Core research for Evolutional Science and Technology) of JST (Japan Science and Technology Agency), Research on Health Sciences focusing on Drug Innovation of The Japan Health Sciences Foundation, and Japan Foundation for Neuroscience and Mental Health.
PY - 2008/1/1
Y1 - 2008/1/1
N2 - Lithium is one of the most commonly used drugs for the treatment of bipolar disorder. To prescribe lithium appropriately to patients, predictors of response to this drug were explored, and several genetic markers are considered to be good candidates. We previously reported a significant association between genetic variations in the breakpoint cluster region (BCR) gene and bipolar disorder. In this study, we examined a possible relationship between response to maintenance treatment of lithium and Asn796Ser single-nucleotide polymorphism in the BCR gene. Genotyping was performed in 161 bipolar patients who had been taking lithium for at least 1 year, and they were classified into responders for lithium mono-therapy and non-responders. We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings.
AB - Lithium is one of the most commonly used drugs for the treatment of bipolar disorder. To prescribe lithium appropriately to patients, predictors of response to this drug were explored, and several genetic markers are considered to be good candidates. We previously reported a significant association between genetic variations in the breakpoint cluster region (BCR) gene and bipolar disorder. In this study, we examined a possible relationship between response to maintenance treatment of lithium and Asn796Ser single-nucleotide polymorphism in the BCR gene. Genotyping was performed in 161 bipolar patients who had been taking lithium for at least 1 year, and they were classified into responders for lithium mono-therapy and non-responders. We found that the allele frequency of Ser796 was significantly higher in non-responders than in responders. Further investigation is warranted to confirm our findings.
UR - http://www.scopus.com/inward/record.url?scp=38349048705&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=38349048705&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2007.08.010
DO - 10.1016/j.pnpbp.2007.08.010
M3 - Article
C2 - 17822820
AN - SCOPUS:38349048705
SN - 0278-5846
VL - 32
SP - 204
EP - 208
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
IS - 1
ER -